CDSCO panel nod to MSN Labs to conduct phase III CT of Elagolix Tablets

Published On 2023-02-20 12:14 GMT | Update On 2023-02-20 12:14 GMT

The drug major MSN Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the proposed Phase III clinical trial of the Elagolix Tablets 150mg & 200mg as per the protocol.

This came in line with the proposal presented by the drug maker MSN Laboratories for grant of permission for manufacturing and marketing of the drug Elagolix Tablets 150mg & 200mg.

For more details, check out the link given below:

MSN Lab Gets CDSCO Panel Nod For Phase III CT Of Elagolix Tablets

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO panel nod to MSN Labs to conduct phase III CT of Elagolix Tablets

Similar News

Indian chest society criticizes NMC for removing respiratory medicine departments amid pollution

Indore doctor dies after colliding car into another vehicle

49,772 PG medical seats in 81 specialities, Maximum in MD General Medicine– NMC matrix

SC delays NEET PG 2024 hearing for the 4th time

Tripura MBBS admissions: 5-year service, Rs 20 lakh bond penalty

NEET PG Counselling: Advisory released on fee, training, joining policies

Calcutta HC denies NEET candidate's migration plea due to Non-receipt of OTP

SC denies relief to Fortis doctor accused of illegal kidney transplants